Interstitial Lung Diseases in the Veterans Administration

Overview

The primary objective of this research project is to describe the characteristics, diagnosis, management, and outcomes of patients with Interstitial Lung Disease (ILD) who received care at the Veteran's Administration Veterans Integrated Service Network (VISN) 6 Mid-Atlantic Health Care Network (VISN6) (includes North Carolina, Virginia and West Virginia) for up to 5 years.

Full Title of Study: “Interstitial Lung Diseases in the Veterans Administration Health System – A Retrospective Description of Patient Characteristics, Management, and Outcomes”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: November 2020

Arms, Groups and Cohorts

  • Interstitial Lung Disease
    • Patients will be identified from a specified 5 year period based on an International Classification of Diseases-9 (ICD-9) code diagnosis of Interstitial Lung disease (515) or Idiopathic Pulmonary Fibrosis (516.3). The patients will be obtained from the records of the Veterans Integrated Service Network (VISN) 6: VA Mid-Atlantic Health Care Network.

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of Interstitial Lung Disease in the VISN6 Veterans Administration Patient Population
    • Time Frame: up to 5 years
  • Prevalence of Idiopathic Pulmonary Fibrosis in the VISN6 Veterans Administration Patient Population
    • Time Frame: up to 5 years

Secondary Measures

  • Accuracy of ICD-9 Codes for diagnosis of Interstitial Lung Disease
    • Time Frame: up to 5 years
    • Will compare the reported ICD-9 code diagnosis with the diagnosis made after chart review and re-interpretation of the lung imaging and pathology
  • Frequency of ICD-9 code diagnosis of Interstitial Lung Disease and clinic consultation with a pulmonary provider
    • Time Frame: up to 5 years
  • Prevalence of Co-morbid Diabetes Mellitus with Interstitial Lung Disease
    • Time Frame: up to five years
    • Compare the prevalence of diabetes with interstitial lung disease as compared to the prevalence of diabetes in the general VA population

Participating in This Clinical Trial

Inclusion Criteria

  • Interstitial Lung Disease (ILD) ICD-9 code diagnosis 515.0 or 516.3

Exclusion Criteria

  • Inadequate documentation of patient receiving care for ILD in the health records

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Robert Tighe
  • Collaborator
    • Durham VA Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Robert Tighe, Staff Physician – Durham VA Medical Center
  • Overall Official(s)
    • Robert M Tighe, MD, Principal Investigator, Duke University Department of Medicine and Durham VA Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.